These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2035723)

  • 41. Haloperidol plasma concentrations in Taiwanese psychiatric patients.
    Lane HY; Lin HN; Hwu HG; Jann M; Hu WH; Chang WH
    J Formos Med Assoc; 1995 Nov; 94(11):671-8. PubMed ID: 8527974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined treatment of schizophrenic psychoses with haloperidol and valproate.
    Dose M; Hellweg R; Yassouridis A; Theison M; Emrich HM
    Pharmacopsychiatry; 1998 Jul; 31(4):122-5. PubMed ID: 9754845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients.
    Jann MW; Chang WH; Davis CM; Chen TY; Deng HC; Lung FW; Ereshefsky L; Saklad SR; Richards AL
    Psychiatry Res; 1989 Oct; 30(1):45-52. PubMed ID: 2594870
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin].
    Gu SF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Dec; 25(6):328-30, 382. PubMed ID: 1304992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reply to Dr. J-C Shim and colleagues regarding "Fluoxetine augmentation of haloperidol in chronic schizophrenia" [J Clin Psychopharmacol 2003;23:520-521].
    Mackin P; Young AH
    J Clin Psychopharmacol; 2004 Dec; 24(6):670. PubMed ID: 15538134
    [No Abstract]   [Full Text] [Related]  

  • 46. [Biochemical mechanisms of extrapyramidal-motoric effect of haloperidol in man].
    Eben E; Ackenheil M; Raese J; Rüther E
    Arzneimittelforschung; 1974 Aug; 24(8):1133-5. PubMed ID: 4479374
    [No Abstract]   [Full Text] [Related]  

  • 47. [Haloperidol decanoate. Results of an open-ended multicentric study in chronic psychotic states].
    Lemperiere T; Ropert R; Leger JM; Alexandre JY; Clerc G; Darondel A; Delaunay J; Delteil P; Malauzat D; Raynaud J
    Encephale; 1984; 10(5):217-22. PubMed ID: 6519017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.
    Moleman P; Schmitz PJ; Ladee GA
    J Clin Psychiatry; 1982 Dec; 43(12):492-6. PubMed ID: 7161250
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blood levels of haloperidol and clinical outcome in schizophrenia.
    Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
    J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring].
    Balant-Gorgia AE; Eisele R; Garrone G
    Schweiz Med Wochenschr; 1985 Jan; 115(1):14-8. PubMed ID: 2857499
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient.
    D'Souza DC; Bennett A; Abi-Dargham A; Krystal JH
    J Clin Psychopharmacol; 1994 Oct; 14(5):361-3. PubMed ID: 7806697
    [No Abstract]   [Full Text] [Related]  

  • 53. Haloperidol reductase activity in red blood cells from oriental patients on haloperidol.
    Someya T; Shibasaki M; Kato T; Noguchi T; Ishida N; Takahashi S
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(2):275-8. PubMed ID: 1871328
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
    Davidson M; Kendler KS; Davis BM; Horvath TB; Mohs RC; Davis KL
    Psychiatry Res; 1985 Oct; 16(2):95-9. PubMed ID: 3865258
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluoxetine and extrapyramidal side effects.
    Coulter DM; Pillans PI
    Am J Psychiatry; 1995 Jan; 152(1):122-5. PubMed ID: 7802102
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Red blood cell/plasma haloperidol ratios and antipsychotic efficacy.
    Neborsky RJ; Janowsky DS; Perel JM
    Psychiatry Res; 1982 Feb; 6(1):123-4. PubMed ID: 6949166
    [No Abstract]   [Full Text] [Related]  

  • 57. Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis.
    Takeda M; Nishinuma K; Yamashita S; Matsubayashi T; Tanino S; Nishimura T
    Clin Neuropharmacol; 1986; 9(4):386-97. PubMed ID: 3731135
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia.
    Kidron R; Averbuch I; Klein E; Belmaker RH
    Biol Psychiatry; 1985 Feb; 20(2):219-22. PubMed ID: 3971003
    [No Abstract]   [Full Text] [Related]  

  • 59. Haloperidol plasma level monitoring in pediatric patients.
    Morselli PL; Bianchetti G; Durand G; Le Heuzey MF; Zarifian E; Dugas M
    Ther Drug Monit; 1979; 1(1):35-46. PubMed ID: 553330
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elevation of plasma homovanillic acid level can be detected within four hours after initiation of haloperidol treatment.
    Davila R; Zumarraga M; Perea K; Andia I; Friedhoff AJ
    Arch Gen Psychiatry; 1987 Sep; 44(9):837-8. PubMed ID: 3632258
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.